Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Kairos Pharma (KAPA)

Kairos Pharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:KAPA
DateTimeSourceHeadlineSymbolCompany
11/02/202513:30Business WireKairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical TrialAMEX:KAPAKairos Pharma Ltd
10/02/202521:45Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsAMEX:KAPAKairos Pharma Ltd
06/02/202514:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
06/02/202513:30Business WireKairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and GlioblastomaAMEX:KAPAKairos Pharma Ltd
05/02/202511:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:KAPAKairos Pharma Ltd
05/02/202505:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:KAPAKairos Pharma Ltd
29/01/202512:22Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsAMEX:KAPAKairos Pharma Ltd
29/01/202511:39Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933AMEX:KAPAKairos Pharma Ltd
28/01/202521:10Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesAMEX:KAPAKairos Pharma Ltd
28/01/202513:15Business WireKairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024AMEX:KAPAKairos Pharma Ltd
21/01/202513:30Business WireKairos Pharma Provides Business Update and Outlook into 2025AMEX:KAPAKairos Pharma Ltd
17/01/202522:20Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
14/01/202514:41Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
07/01/202513:15Business WireKairos Pharma to Present at the Lytham Partners Investor Healthcare SummitAMEX:KAPAKairos Pharma Ltd
13/12/202421:10Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
03/12/202413:30Business WireKairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical TrialAMEX:KAPAKairos Pharma Ltd
19/11/202413:48Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
14/11/202419:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:KAPAKairos Pharma Ltd
10/10/202421:30Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
04/10/202421:29Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
27/09/202421:17Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansAMEX:KAPAKairos Pharma Ltd
27/09/202421:10Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
25/09/202401:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:KAPAKairos Pharma Ltd
24/09/202420:22Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
17/09/202420:15Edgar (US Regulatory)Form 8-K - Current reportAMEX:KAPAKairos Pharma Ltd
17/09/202410:36Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]AMEX:KAPAKairos Pharma Ltd
17/09/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:KAPAKairos Pharma Ltd
 Showing the most relevant articles for your search:AMEX:KAPA